Company: SYRA
Filing Date: 2025-08-12
Form Type: 10-Q
Source: 0001641172-25-023235
Chunk: 96

Company: Syra Health Corp
Filing Date: 2025-08-12
Form: 10-Q
Item: Item 3
Chunk 96
---
The
Company is not required to provide the information required by this Item as it is a “smaller reporting company,” as defined
in Rule 12b-2 of the Exchange Act.

ITEM
4. CONTROLS AND PROCEDURES.

Our
principal executive officer and principal financial officer evaluated the effectiveness of our “disclosure controls and procedures”
as of June 30, 2025 the end of the period covered by this Quarterly Report on Form 10-Q. The term “disclosure controls and procedures”
as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed
to ensure that information required to be disclosed by a company in the reports that it files under the Exchange Act is recorded, processed,
summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include,
without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports
that it files under the Exchange Act is accumulated and communicated to a company’s management, including its principal executive
officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. In designing and evaluating
the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated,
cannot provide absolute assurance that the objectives of the controls system are met, and no evaluation of controls can provide absolute
assurance that all control issues and instances of fraud, if any, within a company have been detected. Based on the evaluation of our
disclosure controls and procedures as of June 30, 2025, our Chief Executive Officer and our Chief Financial Officer concluded that, as
of such date, our disclosure controls and procedures were effective. Effective internal control contemplates an appropriate level of
review to ensure timely preparation and completeness and accuracy of the financial statements and disclosures.

Changes
in Internal Control

There
were no changes in our internal control over financial
reporting that occurred during the three months ended June 30, 2025 that have materially affected, or are reasonably likely to materially
affect, our internal control over financial reporting.

12

PART
II — OTHER INFORMATION

ITEM
1. LEGAL PROCEEDINGS.

From
time to time, we may become involved in various lawsuits and legal proceedings, which arise in the ordinary course of business. Litigation
is subject to inherent uncertainties and an adverse result in